Answers are grounded in this paper and cite their sources.
Systematic review shows GLP-1 receptor agonists may reduce atrial fibrillation risk in overweight populations, suggesting cardioprotective effects independent of weight loss.
Among individuals with overweight or obesity, GLP-1RAs and co-agonists were associated with a lower risk of incident AF event. This cardioprotective benefit may, at least in part, operate independently of the magnitude of weight loss.
No takes yet. Share an insight, caveat, or question.
Karakasis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: